{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:02:53Z","timestamp":1787162573626,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SSGJ-608 is an anti-interleukin-17A monoclonal antibody with high specificity and high affinity and has shown promising efficacy in treatment of moderate-to-severe psoriasis in preliminary trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This multicenter, randomized, open-label, phase 3 trial aimed to further evaluate SSGJ-608 at different dosing intervals (80mg every two weeks and 160mg every four weeks) in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 770 patients with moderate to severe plaque psoriasis were randomly assigned (1:1) to receive subcutaneous injections of 80mg of SSGJ-608 every two weeks (Q2W) after a starting dose of 160mg at week 0(608A group), or 160mg of SSGJ-608 every four weeks (Q4W) (608 B group) for 12 weeks. Efficacy was assessed by PASI75 and sPGA 0 or 1 response rates at week 12 as co-primary endpoints, and proportion of patients who achieved PASI90, PASI100 or sPGA score of 0 at week 12 as secondary endpoints. The safety profile was also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week12, the proportions of patients achieving PASI75 (92.7% vs. 95.1%) and sPGA 0\/1 (80.3% vs. 79.0%) were comparable between the two SSGJ-608 dose regimens. The PASI90, PASI100 and sPGA 0 response rates were 81.0% vs.82.3%, 49.4% vs. 47.5%, and 49.4% vs.47.3% in the 608A group and the 608B group, respectively. In the subgroup of patients previously treated with anti-IL-17 therapy, SSGJ-608 also achieved high clinical response rates at week12. The most common TEAEs were hypertriglyceridemia, upper respiratory tract infection, hyperuricemia, increased alanine aminotransferase and hypercholesterolemia. Both treatment groups demonstrated a favorable safety profile and no new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SSGJ-608 was highly effective for treating patients with moderate-to-severe plaque psoriasis at 80mg Q2W and 160mg Q4W in a larger population, especially in patients previously treated with anti-IL-17 therapy, and exhibited a favorable tolerability profile in Chinese patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/clinicaltrials.gov\/<\/jats:uri>\n                      , identifier NCT06299982.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1810418","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:43:37Z","timestamp":1780983817000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study"],"prefix":"10.3389","volume":"17","author":[{"given":"Lin","family":"Cai","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"The Third Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[{"name":"Hangzhou First People\u2019s Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsuo","family":"Duan","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Chengde Medical University","place":["Chengde, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanying","family":"Qin","sequence":"additional","affiliation":[{"name":"Cangzhou People\u2019s Hospital","place":["Cangzhou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxiang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Jingzhou Central Hospital","place":["Jingzhou, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[{"name":"Dermatology Hospital of Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Ningbo Second Hospital (Huamei Hospital), University of Chinese Academy of Sciences","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Lianyungang","place":["Lianyungang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunfei","family":"Liu","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital, Zhejiang University School of Medicine","place":["Yiwu, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Shanghai Dermatology Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[{"name":"China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Shan","sequence":"additional","affiliation":[{"name":"Hangzhou Third People\u2019s Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[{"name":"The Third Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial People\u2019s Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixin","family":"Chen","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Nanyang","place":["Nanyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Tu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Kunming Medical University","place":["Yunnan, Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[{"name":"Shengli Oilfield Central Hospital","place":["Dongying, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Wuxi Second People\u2019s Hospital","place":["Wuxi, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Qiao","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Qujing","place":["Qujing, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zudong","family":"Meng","sequence":"additional","affiliation":[{"name":"Shiyan People\u2019s Hospital","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Xingtai People\u2019s Hospital","place":["Xingtai, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Yuan","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Changzhou","place":["Changzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjian","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Changde","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Hu","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Guo","sequence":"additional","affiliation":[{"name":"The First Hospital of Shanxi Medical University","place":["Taiyuan, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Xia","sequence":"additional","affiliation":[{"name":"Yantai Yuhuangding Hospital","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Man","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouwei","family":"Wu","sequence":"additional","affiliation":[{"name":"Shanghai General Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[{"name":"Sichuan Provincial People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhi","family":"Chen","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxia","family":"He","sequence":"additional","affiliation":[{"name":"Panjin Liaoyou Gem Flower Hospital","place":["Panjin, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lv","sequence":"additional","affiliation":[{"name":"Yancheng First People\u2019s Hospital","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Feng","sequence":"additional","affiliation":[{"name":"Chengdu Second People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqi","family":"Deng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmei","family":"Geng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[{"name":"Sun Yat-sen Memorial Hospital of Sun Yat-sen University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[{"name":"The Second Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulan","family":"Zhu","sequence":"additional","affiliation":[{"name":"The Second People\u2019s Hospital of Changzhi","place":["Changzhi, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjiang","family":"Lin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushan","family":"Xia","sequence":"additional","affiliation":[{"name":"Jiangyin Hospital of Traditional Chinese Medicine","place":["Jiangyin, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshui","family":"Yu","sequence":"additional","affiliation":[{"name":"Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanli","family":"Fan","sequence":"additional","affiliation":[{"name":"Yuncheng Central Hospital of Shanxi Province","place":["Yuncheng, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Ji","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Xiamen Medical College","place":["Xiamen, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiechi","family":"Lei","sequence":"additional","affiliation":[{"name":"Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Yang","sequence":"additional","affiliation":[{"name":"Jiangxi Provincial People\u2019s Hospital","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[{"name":"Wuhan Central Hospital","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiquan","family":"Li","sequence":"additional","affiliation":[{"name":"Yuebei People\u2019s Hospital","place":["Shaoguan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lou","sequence":"additional","affiliation":[{"name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Liu","sequence":"additional","affiliation":[{"name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17497","article-title":"Psoriasis management tree based on comorbidity","volume":"64","author":"Amara","year":"2025","journal-title":"Int J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50591","article-title":"Beyond skin deep: addressing comorbidities in psoriasis","volume":"212","author":"Kovitwanichkanont","year":"2020","journal-title":"Med J Aust"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715839","article-title":"Stigmatization in patients with psoriasis: a mini review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000528945","article-title":"Patient perspectives on psoriatic disease burden: results from the global psoriasis and beyond survey","volume":"239","author":"Armstrong","year":"2023","journal-title":"Dermatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1586\/14737167.2014.933671","article-title":"The economic burden of psoriasis: a systematic literature review","volume":"14","author":"Feldman","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub6","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00476-w","article-title":"Secukinumab: a review in moderate to severe pediatric plaque psoriasis","volume":"23","author":"Blair","year":"2021","journal-title":"Paediatr Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.044","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Iskandar","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1730326","article-title":"The safety of brodalumab for the treatment of psoriasis","volume":"19","author":"Iznardo","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/bjd\/ljaf032","article-title":"Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe\u00a0plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial\u00a0open-label extension period","volume":"193","author":"Warren","year":"2025","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.031","article-title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"92","author":"Yan","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01261-6","article-title":"Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis","volume":"14","author":"Augustin","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae062","article-title":"A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis","volume":"191","author":"Cai","year":"2024","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/bjd\/ljad315","article-title":"Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis","volume":"190","author":"Jiang","year":"2023","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/JD9.0000000000000244","article-title":"Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study","volume":"5","author":"Li","year":"2022","journal-title":"Int J Dermatol Venereology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J Exp Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1810418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:43:38Z","timestamp":1780983818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1810418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1810418"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1810418","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1810418"}}